SCHEMBL16123519

SCHEMBL16123519

Oc1ccc2c3ccnc(C(F)(F)F)c3n(CCCN3CCOCC3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HASPIN Q8TF76 2/20 0.49
▸ DYRK2 Q92630 1/20 0.49
▸ SRC P12931 2/20 0.39
▸ CHEK1 O14757 3/20 0.38
▸ WEE1 P30291 3/20 0.38
▸ ESR1 P03372 2/20 0.38
▸ ESR2 Q92731 2/20 0.38
▸ CNR2 P34972 1/20 0.37
▸ ABCB1 P08183 1/20 0.37
▸ MAPK13 O15264 2/20 0.37
▸ MAPK12 P53778 2/20 0.37
▸ MAPK11 Q15759 2/20 0.37
▸ MAPK14 Q16539 2/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ TRPV4 Q9HBA0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939888 1.00 HASPIN (0.49) HASPINDYRK2SRCCHEK1WEE1
SCHEMBL30939873 0.98 HASPIN (0.52) HASPINDYRK2SRCCHEK1WEE1
SCHEMBL16123619 0.98 HASPIN (0.52) HASPINDYRK2SRCCHEK1WEE1
SCHEMBL30939941 0.95 HASPIN (0.47) HASPINDYRK2CHEK1WEE1ESR1
SCHEMBL16123614 0.95 HASPIN (0.47) HASPINDYRK2CHEK1WEE1ESR1
SCHEMBL30939883 0.88 HASPIN (0.49) HASPINDYRK2ESR1ESR2
SCHEMBL16102630 0.88 HASPIN (0.49) HASPINDYRK2ESR1ESR2
SCHEMBL30939917 0.86 HASPIN (0.48) HASPINDYRK2ESR1ESR2
SCHEMBL16101221 0.86 HASPIN (0.48) HASPINDYRK2ESR1ESR2
SCHEMBL16123501 0.85 HASPIN (0.69) HASPINDYRK2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3915987-B1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSTEOQC INC (CA) 2023-12-13 — — EP disclosed
EP-3915987-B1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSTEOQC INC (CA) 2023-12-13 — — EP disclosed
US-11267814-B2 Compounds for bone growth OsteoQC, Inc. 2022-03-08 — — US disclosed
EP-3915987-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH Osteoqc Inc. (CA) 2021-12-01 — — EP disclosed
EP-3915987-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH Osteoqc Inc. (CA) 2021-12-01 — — EP disclosed
CN-113416187-A Alkylamine peganine derivatives for promoting bone growth 奥斯特克有限公司 2021-09-21 — — CN disclosed
CN-105120863-B Alkylamine peganine derivatives for promoting bone growth 奥斯特克有限公司 2021-06-04 — — CN disclosed
EP-2968284-B1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSTEOQC INC (CA) 2021-04-21 — — EP disclosed
EP-2968284-B1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSTEOQC INC (CA) 2021-04-21 — — EP disclosed
US-20200172538-A1 COMPOUNDS FOR BONE GROWTH OSSIFI THERAPEUTICS LLC 2020-06-04 — — US disclosed
US-20200172538-A1 COMPOUNDS FOR BONE GROWTH OSSIFI THERAPEUTICS LLC 2020-06-04 — — US disclosed
US-20170298059-A1 COMPOUNDS FOR BONE GROWTH OSSIFI THERAPEUTICS LLC 2017-10-19 — — US disclosed
US-20170298059-A1 COMPOUNDS FOR BONE GROWTH OSSIFI THERAPEUTICS LLC 2017-10-19 — — US disclosed
US-20170298059-A1 COMPOUNDS FOR BONE GROWTH OSSIFI THERAPEUTICS LLC 2017-10-19 — — US disclosed
US-9540365-B2 Compounds for bone growth OSTEOQC INC. (CA) 2017-01-10 — — US disclosed
US-9540365-B2 Compounds for bone growth OSTEOQC INC. (CA) 2017-01-10 — — US disclosed
WO-2014153203-A2 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSSIFI INC. (US) 2014-09-25 — — WO disclosed
US-20140288068-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSSIFI INC. (US) 2014-09-25 — — US disclosed
US-20140288068-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSSIFI INC. (US) 2014-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172538-A1 COMPOUNDS FOR BONE GROWTH FGF1, FGF2, BMP2 HASPIN 1246/4885DYRK2 4607/4885SRC 3643/4885
US-20170298059-A1 COMPOUNDS FOR BONE GROWTH FGF1, FGF2, BMP2 HASPIN 1246/4885DYRK2 4607/4885SRC 3643/4885
US-11267814-B2 Compounds for bone growth FGF1, FGF2, BMP2 HASPIN 1246/4885DYRK2 4607/4885SRC 3643/4885
US-20140288068-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH TPH1, TPH2, HTR5A HASPIN 696/4885DYRK2 3323/4885SRC 4262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback